Independent Research Describes ANAVEX 3-71 as Potent Cognitive Enhancer in Alzheimer’s Disease Models
New Exploratory Alzheimer’s Drug ANAVEX 2-73: Assessment of Safety and Cognitive Performance in a Phase 2a Study in mild-to-moderate Alzheimer’s Patients.
Anavex to Present at American Epilepsy Society Annual Meeting ANAVEX 2-73 Demonstrates Anti-Seizure Effects in Well Established Preclinical Seizure Models
New Exploratory Alzheimer’s Drug ANAVEX 2-73 Changes in Electrophysiological Markers in Alzheimer’s Disease – First Patient Data from an ongoing Phase 2a Study in mild-to-moderate Alzheimer’s Patients.
